iOnctura is tackling the PI3K Delta target, a mechanism with known efficacy but a history of severe side effects. By developing an allosteric modulator, they've engineered a drug (Roganolisib) with a significantly improved safety profile, aiming to unlock the target's full potential without its historical "baggage."
iOnctura's CEO sees potential success from first-line treatments by Immunocore and Ideia as a positive development. Because patients on these drugs will eventually progress, their approval establishes a larger, well-defined second-line market where iOnctura's Roganolisib is positioned to become the standard of care.
Instead of running separate Phase 2 and 3 trials, iOnctura plans to "operationally upsize" its current study. This involves keeping the same clinical sites open and transitioning directly into a Phase 3 cohort with new patients, creating a more efficient, faster, and less costly path to potential approval.
Beyond its current late-stage trial, iOnctura's key ambition is to use its well-tolerated oral drug in the adjuvant setting. The goal is to prevent metastasis in the 50% of patients who relapse after primary eye treatment, fundamentally changing their prognosis rather than just managing late-stage disease.